Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study.
Cheng-Wei HuangLewei DuanJaejin AnJohn J SimMing-Sum LeePublished in: Journal of general internal medicine (2021)
Among AF patients with a BMI >40kg/m2 or a weight >120kg in a real-world clinical setting, dabigatran was effective in reducing the risk of thromboembolism and mortality but was associated with an increased risk of bleeding when compared to warfarin. Dabigatran may be a reasonable option for AF patients with severe obesity.
Keyphrases
- atrial fibrillation
- weight gain
- weight loss
- oral anticoagulants
- insulin resistance
- left atrial
- catheter ablation
- metabolic syndrome
- direct oral anticoagulants
- body mass index
- left atrial appendage
- type diabetes
- high fat diet induced
- early onset
- heart failure
- percutaneous coronary intervention
- cardiovascular events
- physical activity
- risk factors
- cardiovascular disease
- coronary artery disease
- left ventricular
- acute coronary syndrome
- skeletal muscle
- mitral valve